Skip to main content
SpringerLink
Log in

Immune Monitoring

  • Chapter
Tumor Immunology and Cancer Vaccines

Part of the book series: Cancer Treatment and Research ((CTAR,volume 123))

Abstract

A wide array of immunologic tests are available for immune monitoring in cancer vaccine trials, and the number of novel assays and technical modifications continues to burgeon. Because only a small fraction of all proposed vaccine trials tested in phase I-II trials, for practical reasons, will ultimately move forward to be tested in phase III trials, there must be a system of establishing the most promising immunization strategies. This evaluation of cancer vaccine will require standardization of the immune assays and statistical methods used in immunologic monitoring. Furthermore, the use of a systematic approach to evaluating and adopting novel technologies for immunologic assessment would likely lead to timely implementation of more reliable, practical and cost-effective methods of immune. It should be the goal and expectation that this rational approach to immune monitoring will allow the critical appraisal of the most promising vaccine candidates in the context of pivotal, multi-center trials.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

6. References

  1. Varis, T., and T. Vesikari. 1996. Efficacy of high-titer live attenuated varicella vaccine in healthy young children. J Infect Dis 174:S330–334.

    PubMed  Google Scholar 

  2. Cassidy, W.M. 2001. Adolescent hepatitis B vaccination. A review. Minerva Pediatr 53:559–566.

    PubMed  CAS  Google Scholar 

  3. Therasse, P., S.G. Arbuck, E.A. Eisenhauer et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. JNCI. 92:205–216.

    Google Scholar 

  4. Kobayashi, K., K. Kaneda, and T. Kasama. 2001. Immunopathogenesis of delayed-type hypersensitivity. Microsc Res Tech 53:241–245.

    Article  PubMed  CAS  Google Scholar 

  5. Simons, J.W., B. Mikhak, J.F. Chang et al. 1999. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 59:5160–5168.

    PubMed  CAS  Google Scholar 

  6. Disis, M.L., K. Schiffman, T.A. Gooley, D.G. McNeel, K. Rinn, and K.L. Knutson. 2000. Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization. Clin Cancer Res 6:1347–1350.

    PubMed  CAS  Google Scholar 

  7. Jager, E., S. Gnjatic, Y. Nagata et al. 2000. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci U S A 97:12198–12203.

    Article  PubMed  CAS  Google Scholar 

  8. Schott, M., J. Feldkamp, M. Klucken, G. Kobbe, W.A. Scherbaum, and J. Seissler. 2002. Calcitonin-specific antitumor immunity in medullary thyroid carcinoma following dendritic cell vaccination. Cancer Immunol Immunother 51:663–668.

    Article  PubMed  CAS  Google Scholar 

  9. Thurner, B., I. Haendle, C. Roder et al. 1999. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190:1669–1678.

    Article  PubMed  CAS  Google Scholar 

  10. Morse, M.A., Y. Deng, D. Coleman et al. 1999. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res 5:1331–1338.

    PubMed  CAS  Google Scholar 

  11. McNeel, D.G., K. Schiffman, and M.L. Disis. 1999. Immunization with recombinant human granulocyte-macrophage colony-stimulating factor as a vaccine adjuvant elicits both a cellular and humoral response to recombinant human granulocyte-macrophage colony-stimulating factor. Blood 93:2653–2659.

    PubMed  CAS  Google Scholar 

  12. Barratt-Boyes, S.M., H. Kao, and O.J. Finn. 1998. Chimpanzee dendritic cells derived in vitro from blood monocytes and pulsed with antigen elicit specific immune responses in vivo. J Immunother 21:142–148.

    Article  PubMed  CAS  Google Scholar 

  13. Hsueh, E.C., R. Essner, L.J. Foshag et al. 2002. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol 20:4549–4554.

    Article  PubMed  CAS  Google Scholar 

  14. Lee, K.H., E. Wang, M.B. Nielsen et al. 1999. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol 163:6292–6300.

    PubMed  CAS  Google Scholar 

  15. Panelli, M.C., A. Riker, U. Kammula et al. 2000. Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases. J Immunol 164:495–504.

    PubMed  CAS  Google Scholar 

  16. Phan, G.Q., E. Wang, and F.M. Marincola. 2001. T-cell-directed cancer vaccines: mechanisms of immune escape and immune tolerance. Expert Opin Biol Ther 1:511–523.

    Article  PubMed  CAS  Google Scholar 

  17. Pittet, M.J., D. Valmori, P.R. Dunbar et al. 1999. High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med 190:705–715.

    Article  PubMed  CAS  Google Scholar 

  18. Yamshchikov, G.V., D.L. Barnd, S. Eastham et al. 2001. Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients. Int J Cancer 92:703–711.

    Article  PubMed  CAS  Google Scholar 

  19. Conry, R.M., A.F. LoBuglio, F. Loechel et al. 1995. A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity. Gene Ther 2:59–65.

    PubMed  CAS  Google Scholar 

  20. Jager, E., Y. Nagata, S. Gnjatic et al. 2000. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci U S A 97:4760–4765.

    Article  PubMed  CAS  Google Scholar 

  21. Tsioulias, G.J, R.K. Gupta, G. Tisman et al. 2001. Serum TA90 antigen-antibody complex as a surrogate marker for the efficacy of a polyvalent allogeneic whole-cell vaccine (CancerVax) in melanoma. Ann Surg Oncol 8:198–203.

    Article  PubMed  CAS  Google Scholar 

  22. Khleif, S.N., S.I. Abrams, J.M. Hamilton et al. 1999. A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors. J Immunother 22:155–165.

    PubMed  CAS  Google Scholar 

  23. Disis, M.L., K.H. Grabstein, P.R. Sleath, and M.A. Cheever. 1999. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 5:1289–1297.

    PubMed  CAS  Google Scholar 

  24. Sandmaier, B.M., D.V. Oparin, L.A. Holmberg, M.A. Reddish, G.D. MacLean, and B.M. Longenecker. 1999. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine. J Immunother 22:54–66.

    Article  PubMed  CAS  Google Scholar 

  25. Schreiber, S., E. Kampgen, E. Wagner et al. 1999. Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: outcome of a phase I study. Human Gene Ther 10:983–993.

    Article  CAS  Google Scholar 

  26. Givan, A.L., J.L. Fisher, M. Waugh, M.S. Ernstoff, and P.K. Wallace. 1999. A flow cytometric method to estimate the precursor frequencies of cells proliferating in response to specific antigens. J Immunol Methods 230:99–112.

    Article  PubMed  CAS  Google Scholar 

  27. Mattis, A.E., G. Bernhardt, M. Lipp, and R. Forster. 1997. Analyzing cytotoxic T lymphocyte activity: a simple and reliable flow cytometry-based assay. J Immunol Methods 204:135–142.

    Article  PubMed  CAS  Google Scholar 

  28. Aubry, J.P., A. Blaecke, S. Lecoanet-Henchoz et al. 1999. Annexin V used for measuring apoptosis in the early events of cellular cytotoxicity. Cytometry 37:197–204.

    Article  PubMed  CAS  Google Scholar 

  29. Derby, E., V. Reddy, W. Kopp et al. 2001. Three-color flow cytometric assay for the study of the mechanisms of cell-mediated cytotoxicity. Immunol Lett 78:35–39.

    Article  PubMed  CAS  Google Scholar 

  30. van Oers, M.H., J. Pinkster, and W.P. Zeijlemaker. 1978. Quantification of antigen-reactive cells among human T lymphocytes. Eur J Immunol 8:477–484.

    Article  PubMed  Google Scholar 

  31. Mackensen, A., H. Veelken, M. Lahn et al. 1997. Induction of tumor-specific cytotoxic T lymphocytes by immunization with autologous tumor cells and interleukin-2 gene transfected fibroblasts. J Mol Med 75:290–296.

    Article  PubMed  CAS  Google Scholar 

  32. Kourilsky, P., P. Bousso, S. Calbo, and L. Gapin. 1998. Immunological issues in vaccine trials: T-cell responses. Dev Biol Stand 95:117–124.

    PubMed  CAS  Google Scholar 

  33. McKee, M.D., T.M. Clay, S.A. Rosenberg, M.I. Nishimura. 1999. Quantitation of T-cell receptor frequencies by competitive PCR: generation and evaluation of novel TCR subfamily and clone specific competitors. J Immunother 22:93–102.

    Article  PubMed  CAS  Google Scholar 

  34. Lue, C., Y. Mitani, M.D. Crew, J.F. George, L.M. Fink, and S.A. Schichman. 1999. An automated method for the analysis of T-cell receptor repertoires. Rapid RT-PCR fragment length analysis of the T-cell receptor beta chain complementarity-determining region 3. Am J Clin Pathol 111:683–690.

    PubMed  CAS  Google Scholar 

  35. Altman, J.D., P.A.H. Moss, P.J.R. Goulder et al. 1996. Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94–96.

    Article  PubMed  CAS  Google Scholar 

  36. Dal Porto, J., T.E. Johansen, B. Catipovi et al. 1993. A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations. Proc Natl Acad Sci U S A 90:6671–6675.

    Article  Google Scholar 

  37. Fahmy, T.M., J.G. Bieler, and J.P. Schneck. 2002. Probing T cell membrane organization using dimeric MHC-Ig complexes. J Immunol Methods 268:93–106.

    Article  PubMed  CAS  Google Scholar 

  38. Romero, P., P.R. Dunbar, D. Valmori et al. 1998. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 188:1641–1650.

    Article  PubMed  CAS  Google Scholar 

  39. Dhodapkar, M.V., R.M. Steinman, M. Sapp et al. 1999. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest 104:173–180.

    Article  PubMed  CAS  Google Scholar 

  40. Dunbar, P.R., G.S. Ogg, J. Chen, N. Rust, P. van der Bruggen, V. Cerundolo. 1998. Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood. Curr Biol 8:413–416.

    Article  PubMed  CAS  Google Scholar 

  41. Novak, E.J., A.W. Liu, G.T. Nepom, and W.W. Kwok. 1999. MHC class II tetramers identify peptide-specific human CD4(+) T cells proliferating in response to influenza A antigen. J Clin Invest 104:R63–67.

    PubMed  CAS  Google Scholar 

  42. Nepom, G.T., J.H. Buckner, E.J. Novak et al. 2002. HLA class II tetramers: tools for direct analysis of antigen-specific CD4+ T cells. Arthritis Rheum 46:5–12.

    Article  PubMed  CAS  Google Scholar 

  43. He, X.S., B. Rehermann, J. Boisvert et al. 2001. Direct functional analysis of epitope-specific CD8+ T cells in peripheral blood. Viral Immunol 14:59–69.

    Article  PubMed  CAS  Google Scholar 

  44. Swartzman, E.E., S.J. Miraglia, J. Mellentin-Michelotti, L. Evangelista, and P.M. Yuan. 1999. A homogeneous and multiplexed immunoassay for high-throughput screening using fluorometric microvolume assay technology. Anal Biochem 271:143–151.

    Article  PubMed  CAS  Google Scholar 

  45. Snyder, J.E., W.J. Bowers, A.M. Livingstone, F.E. Lee, H.J. Federoff, and T.R. Mosmann. 2003. Measuring the frequency of mouse and human cytotoxic T cells by the Lysispot assay: independent regulation of cytokine secretion and short-term killing. Nat Med 9:231–235.

    Article  PubMed  CAS  Google Scholar 

  46. Asai, T., W.J. Storkus, and T.L. Whiteside. 2000. Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines. Clin Diagn Lab Immunol 7:145–154.

    Article  PubMed  CAS  Google Scholar 

  47. Scheibenbogen, C., P. Romero, L. Rivoltini et al. 2000. Quantitation of antigen-reactive T cells in peripheral blood by IFNgamma-ELISPOT assay and chromium-release assay: a four-centre comparative trial. J Immunol Methods 244:81–89.

    Article  PubMed  CAS  Google Scholar 

  48. Wang, F., E. Bade, C. Kuniyoshi et al. 1999. Phase I trial of a MART-1 peptide vaccine with incomplete Freund’s adjuvant for resected high-risk melanoma. Clin Cancer Res 5:2756–2765.

    PubMed  CAS  Google Scholar 

  49. Arlen, P., K.Y. Tsang, J.L. Marshall et al. 2000. The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines. Cancer Immunol Immunother 49:517–529.

    Article  PubMed  CAS  Google Scholar 

  50. von Mehren. M., P. Arlen, J. Gulley et al. 2001. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res 7:1181–1191.

    Google Scholar 

  51. Belli, F., A. Testori, L. Rivoltini et al. 2002. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol 20:4169–4180.

    Article  PubMed  CAS  Google Scholar 

  52. Mosca, P.J., A.C. Hobeika, T.M. Clay et al. 2000. A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-gamma treatment. Blood 96:3499–3504.

    PubMed  CAS  Google Scholar 

  53. Pittet, M.J., A. Zippelius, D.E. Speiser et al. 2001. Ex vivo IFN-gamma secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseases. J Immunol 166:7634–7640.

    PubMed  CAS  Google Scholar 

  54. Heid, C.A., J. Stevens, K.J. Livak, and P.M. Williams. 1996. Real time quantitative PCR. Genome Res 6:986–994.

    Article  PubMed  CAS  Google Scholar 

  55. Asselin-Paturel, C., H. Echchakir, G. Carayol et al. 1998. Quantitative analysis of Th1, Th2 and TGF-beta1 cytokine expression in tumor, TIL and PBL of non-small cell lung cancer patients. Int J Cancer 77:7–12.

    Article  PubMed  CAS  Google Scholar 

  56. Hauer, A.C., M. Bajaj-Elliott, C.B. Williams, J.A. Walker-Smith, T.T. MacDonald. 1998. An analysis of interferon gamma, IL-4, IL-5 and IL-10 production by ELISPOT and quantitative reverse transcriptase-PCR in human Peyer’s patches. Cytokine 10:627–634.

    Article  PubMed  CAS  Google Scholar 

  57. Kammula, U.S., K.H. Lee, A.I. Riker et al. 1999. Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. J Immunol 163:6867–6875.

    PubMed  CAS  Google Scholar 

  58. Petricoin, E.F., A.M. Ardekani, B.A. Hitt et al. 2002. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359:572–577.

    Article  PubMed  CAS  Google Scholar 

  59. Keilholz, U., J. Weber, J.H. Finke et al. 2002. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 25:97–138.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Surgery, Internal Medicine, Pathology, and Immunology, Duke University Medical Center, Durham, NC, 27710

    Paul J. Mosca (Attending), Timothy M. Clay, Michael A. Morse & H. Kim Lyerly

  2. Department of Surgery, Lehigh Valley Hospital, USA

    Paul J. Mosca (Attending)

Authors
  1. Paul J. Mosca
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Timothy M. Clay
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael A. Morse
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Kim Lyerly
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Vaccine Branch, National Cancer Institute, Bethesda Naval Hospital Bethesda, MD, USA

    Samir N. Khleif

  2. King Hussein Cancer Center, Amman, Jordan

    Samir N. Khleif

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Kluwer Academic Publishers

About this chapter

Cite this chapter

Mosca, P.J., Clay, T.M., Morse, M.A., Lyerly, H.K. (2005). Immune Monitoring. In: Khleif, S.N. (eds) Tumor Immunology and Cancer Vaccines. Cancer Treatment and Research, vol 123. Springer, Boston, MA. https://doi.org/10.1007/0-387-27545-2_16

Download citation

  • DOI: https://doi.org/10.1007/0-387-27545-2_16

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4020-8119-4

  • Online ISBN: 978-0-387-27545-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation